BlackRock
ANTX icon

BlackRock’s AN2 Therapeutics ANTX Stock Holding History

BlackRock’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.42M Buy
1,771,563
+106,069
+6% +$562K ﹤0.01% 3710
2026
Q2 		$8.06M Buy
1,665,494
+1,346,726
+422% +$5.79M ﹤0.01% 3770
2026
Q1 		$1.09M Sell
318,768
-4,567
-1% -$9.42K ﹤0.01% 4316
2025
Q4 		$369K Buy
323,335
+2,424
+0.8% +$2.83K ﹤0.01% 4567
2025
Q3 		$408K Buy
320,911
+1,616
+0.5% +$1.85K ﹤0.01% 4506
2025
Q2 		$338K Buy
319,295
+18,609
+6% +$22.2K ﹤0.01% 4533
2025
Q1 		$409K Sell
300,686
-735
-0.2% -$925 ﹤0.01% 4449
2024
Q4 		$416K Buy
301,421
+245
+0.1% +$297 ﹤0.01% 4458
2024
Q3 		$322K Buy
301,176
+1,473
+0.5% +$2.56K ﹤0.01% 4427
2024
Q2 		$644K Buy
299,703
+8,617
+3% +$20.5K ﹤0.01% 4280
2024
Q1 		$946K Sell
291,086
-14,755
-5% -$161K ﹤0.01% 4210
2023
Q4 		$6.27M Buy
305,841
+263,679
+625% +$4.41M ﹤0.01% 3601
2023
Q3 		$678K Buy
42,162
+18,680
+80% +$212K ﹤0.01% 4340
2023
Q2 		$200K Sell
23,482
-459,947
-95% -$3.31M ﹤0.01% 4735
2023
Q1 		$4.77M Buy
483,429
+38,220
+9% +$425K ﹤0.01% 3653
2022
Q4 		$4.24M Buy
445,209
+256,924
+136% +$3.44M ﹤0.01% 3799
2022
Q3 		$3.27M Buy
188,285
+1,175
+0.6% +$13.7K ﹤0.01% 3942
2022
Q2 		$1.45M Buy
+187,110
New +$2.48M ﹤0.01% 4385

Other funds holding ANTX

Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
Spruce Street Capital
Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Prosight Management
Prosight Management Dallas, Texas $515M AUM 2.95% 1-Year Est. Return
Stonepine Capital Management
Stonepine Capital Management Bend, Oregon $159M AUM 62.27% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

BlackRock's ANTX Position: Q3 2026 in Review

BlackRock increased its AN2 Therapeutics (ANTX) stake by 6.4% in Q3 2026, buying an estimated $562K and bringing the position to 1,771,563 shares worth $9.42M. The position accounts for ﹤0.01% of the portfolio, ranked #3710.

BlackRock first reported a position in ANTX in Q2 2022 and has held it in 18 quarters since. 51 funds tracked by Wall St. Rank hold ANTX as of Q3 2026.

  • BlackRock held 1,771,563 shares of AN2 Therapeutics worth $9.42M as of Q3 2026.
  • BlackRock bought 106,069 AN2 Therapeutics shares in Q3 2026, an estimated $562K.
  • AN2 Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q3 2026, its #3710 holding.
  • BlackRock first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 18 quarters since.
  • 51 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2026.

Based on BlackRock's 13F filing for Q3 2026, filed 13 Nov 2026.